溶瘤呼肠孤病毒作为抗病毒与抗肿瘤联合制剂治疗肝癌
本文探索溶瘤病毒(OV)诱导的先天免疫应答能否在抑制丙型肝炎病毒(HCV)的同时抑制肝细胞癌(HCC),并将该范例扩展至其他病毒相关肿瘤模型。临床级溶瘤正呼肠孤病毒(Reo)可在原代人肝组织中激活先天免疫而不产生细胞毒性,且不依赖病毒基因组复制;在HCC临床前模型中通过激活先天脱颗粒免疫细胞实现治疗,同时Reo诱导的细胞因子应答在体外和体内有效抑制HCV复制。Reo诱导的先天应答对HBV相关HCC模型及EBV相关淋巴瘤模型也有效,且Reo在原代肝组织中 eliciting 先天炎症应答的能力似乎优于大多数OV。作者提出Reo及其他选定的促炎性OV可用于治疗多种与致癌病毒感染相关的癌症,同时降低病毒相关致癌驱动和肿瘤负荷;对于HCV相关HCC,Reo应被视为补充和支持现有HCV-HCC治疗的替代药物,尤其是在获取新型HCV抗病毒治疗受限的国家。
要点
- 临床级溶瘤正呼肠孤病毒(Reo)可在原代人肝组织中激活先天免疫,不产生细胞毒性且不依赖病毒基因组复制。
- Reo在HCC临床前模型中通过激活先天脱颗粒免疫细胞实现治疗,其诱导的细胞因子应答在体外和体内有效抑制HCV复制。
- Reo诱导的先天应答对HBV相关HCC模型及EBV相关淋巴瘤模型也有效,且Reo在原代肝组织中 eliciting 先天炎症应答的能力似乎优于大多数OV。
核心结论
- 作者提出Reo及其他选定的促炎性OV可用于治疗多种与致癌病毒感染相关的癌症,同时降低病毒相关致癌驱动和肿瘤负荷。
- 对于HCV相关HCC,Reo应被视为补充和支持现有HCV-HCC治疗的替代药物,尤其是在获取新型HCV抗病毒治疗受限的国家。
研究设计与样本
- 研究探索溶瘤病毒(OV)诱导的先天免疫应答能否同时抑制HCV和抑制HCC,并将该范例扩展至其他病毒相关肿瘤模型。
- 使用临床级溶瘤正呼肠孤病毒(Reo)在原代人肝组织及HCC、HBV相关HCC、EBV相关淋巴瘤等临床前模型中进行研究。
主要发现
- 临床级Reo在原代人肝组织中诱导先天免疫激活,不产生细胞毒性且不依赖病毒基因组复制。
- Reo在HCC临床前模型中通过激活先天脱颗粒免疫细胞实现治疗。
- Reo诱导的细胞因子应答在体外和体内有效抑制HCV复制。
- Reo诱导的先天应答对HBV相关HCC模型及EBV相关淋巴瘤模型也有效。
- Reo在原代肝组织中 eliciting 先天炎症应答的能力似乎优于大多数OV。
临床怎么用
- 作者提出Reo及其他选定的促炎性OV可用于治疗多种与致癌病毒感染相关的癌症,同时降低病毒相关致癌驱动和肿瘤负荷。
- 作者认为对于HCV相关HCC,Reo应被视为补充和支持现有HCV-HCC治疗的替代药物,尤其是在获取新型HCV抗病毒治疗受限的国家。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Oncolytic viruses (OVs) represent promising, proinflammatory cancer treatments. Here, we explored whether OV-induced innate immune responses could simultaneously inhibit HCV while suppressing hepatocellular carcinoma (HCC). Furthermore, we extended this exemplar to other models of virus-associated cancer. DESIGN AND RESULTS: Clinical grade oncolytic orthoreovirus (Reo) elicited innate immune activation within primary human liver tissue in the absence of cytotoxicity and independently of viral genome replication. As well as achieving therapy in preclinical models of HCC through the activation of innate degranulating immune cells, Reo-induced cytokine responses efficiently suppressed HCV replication both in vitro and in vivo. Furthermore, Reo-induced innate responses were also effective against models of HBV-associated HCC, as well as an alternative endogenous model of Epstein-Barr virus-associated lymphoma. Interestingly, Reo appeared superior to the majority of OVs in its ability to elicit innate inflammatory responses from primary liver tissue. CONCLUSIONS: We propose that Reo and other select proinflammatory OV may be used in the treatment of multiple cancers associated with oncogenic virus infections, simultaneously reducing both virus-associated oncogenic drive and tumour burden. In the case of HCV-associated HCC (HCV-HCC), Reo should be considered as an alternative agent to supplement and support current HCV-HCC therapies, particularly in those countries where access to new HCV antiviral treatments may be limited.
引用
- Samson A, Bentham MJ, Scott K, et al. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut. 2016. PMID: 27902444. doi:10.1136/gutjnl-2016-312009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。